0000912282-17-000133.txt : 20170526 0000912282-17-000133.hdr.sgml : 20170526 20170526133657 ACCESSION NUMBER: 0000912282-17-000133 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170524 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20170526 DATE AS OF CHANGE: 20170526 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Arbutus Biopharma Corp CENTRAL INDEX KEY: 0001447028 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 980597776 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34949 FILM NUMBER: 17873138 BUSINESS ADDRESS: STREET 1: 100-8900 GLENLYON PARKWAY CITY: BURNABY STATE: A1 ZIP: V5J 5J8 BUSINESS PHONE: 604-419-3200 MAIL ADDRESS: STREET 1: 100-8900 GLENLYON PARKWAY CITY: BURNABY STATE: A1 ZIP: V5J 5J8 FORMER COMPANY: FORMER CONFORMED NAME: TEKMIRA PHARMACEUTICALS Corp DATE OF NAME CHANGE: 20110607 FORMER COMPANY: FORMER CONFORMED NAME: TEKMIRA PHARMACEUTICALS CORP DATE OF NAME CHANGE: 20081003 8-K 1 arbutus8k_052517.htm


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

May 24, 2017
(Date of Report - date of earliest event reported)

Arbutus Biopharma Corporation
(Exact Name of Registrant as Specified in Its Charter)


British Columbia, Canada
(State or Other Jurisdiction of
Incorporation or Organization)
001-34949
(Commission File Number)
98-0597776
(I.R.S. Employer
Identification No.)
     
100-8900 Glenlyon Parkway
Burnaby, British Columbia, Canada
 (Address of Principal Executive Offices)
  
 
V5J 5J8
(Zip Code)

(604) 419-3200
 (Registrant's Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))






Item 5.07.  Submission of Matters to a Vote of Security Holders.

On May 24, 2017, the Corporation held its Annual General Meeting of Shareholders.  At the meeting, shareholders voted in favor of all items of business, as indicated below:

Proposal 1.  The Corporation’s shareholders voted to elect the following persons to the board of directors of the Corporation, each to serve until the 2018 Annual General Meeting:

Nominee
Votes For
%
For
Votes
Withheld
%
Withheld
Broker Non-
Votes
Vivek Ramaswamy
25,146,794
99.63
93,349
0.37
3,264,375
Mark J. Murray
25,097,915
99.44
142,228
0.56
3,264,375
Daniel D. Burgess
25,155,577
99.66
84,566
0.34
3,264,375
Herbert J. Conrad
25,150,938
99.65
89,205
0.35
3,264,375
Richard C. Henriques
25,153,648
99.66
86,495
0.34
3,264,375
Frank Karbe
25,145,200
99.62
94,943
0.38
3,264,375
Keith Manchester
25,108,567
99.48
131,576
0.52
3,264,375
William T. Symonds
25,152,619
99.65
87,524
0.35
3,264,375

Proposal 2.  The Corporation’s shareholders voted to ratify the appointment of KPMG LLP as independent auditor of the Corporation for the fiscal year ended December 31, 2017:

Votes For
%
For
Votes
Against
%
Against
Abstain
28,466,386
99.87
21,898
0.13
16,234

1
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:  May 25, 2017

 

ARBUTUS BIOPHARMA CORPORATION


 
By:
/s/ Bruce Cousins                                                            
Name:
Bruce Cousins
Title:
Executive Vice President & Chief Financial Officer



2